Immuneering to Reveal Q4 & Full Year 2022 Financials & Business Updates – What Will the Future Hold?

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing innovative medicines to treat a broad range of cancer patients, will be reporting its fourth quarter and full year results for the period ending December 31, 2022 on Monday, March 6. Following the close of markets, the company’s management team will be hosting a conference call and webcast to discuss the results at 4:30 p.m. ET. Don’t miss out on this great opportunity to hear about the company’s progress in developing a universal-RAS therapy and other exciting news!

To ensure a smooth start to the conference call, we invite all participants to dial in at least fifteen minutes ahead of the scheduled start time. Access the call by phone using the provided registration link. After the live webcast, the event will be available online in the Investor Relations section of Immuneering’s website under Events & Presentations for a period of 90 days. Don’t miss out!

About Immuneering Corporation

Immuneering is a clinical-stage oncology company revolutionizing cancer treatment with a universal-RAS therapy that targets cancer cells while leaving healthy cells unharmed. Their lead product candidate, IMM-1-104, is currently in a Phase 1/2a study for advanced solid tumors with RAS mutations, and their development pipeline includes IMM-6-415, designed for accelerated cadence, as well as several other early-stage programs. By utilizing deep cyclic inhibition of the MAPK pathway, Immuneering is paving the way for effective and safe cancer treatments.

Leave a Comment